Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC
The impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the development of cirrhosis and hepatocellular carcinoma (HCC) by chronic hepatitis B (CHB) or C infection and antiviral treatment statuses is not well known.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Mei-Hsuan Lee, Yi-Ting Chen, Yu-Han Huang, Sheng-Nan Lu, Tsai-Hsuan Yang, Jee-Fu Huang, Szu-Ching Yin, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Hwai-I Yang, Hsuan-Yu Chen, Chien-Jen Chen Source Type: research
More News: Cancer & Oncology | Carcinoma | Chia | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Urology & Nephrology